Valuation: Iqvia Holdings

Market Cap 42.78B 38.2B 35.54B 32.33B 61.03B 4,140B 61.3B 428B 168B 2,111B 161B 157B 6,773B P/E 2026 *
33.5x
P/E 2027 * 26.8x
Enterprise Value 56.62B 50.57B 47.04B 42.79B 80.78B 5,479B 81.13B 566B 222B 2,794B 213B 208B 8,965B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 3.03x
Free-Float
62.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 64 2016-10-02
Director of Finance/CFO 51 2026-02-27
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 68 2015-02-04
Chairman 64 2016-10-02
Director/Board Member 69 2016-10-02
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%+2.60% - - 42.78B
-2.59%-5.70%+39.83%+82.45% 70.61B
+3.23%-10.67%+4.87%+55.97% 51.01B
+1.56%+1.17%+5.15%+33.38% 48.1B
+0.39%+0.65%+28.02%+30.24% 42.78B
+0.87%-8.17%+298.53%+645.03% 40.67B
+1.24%-1.01%+5.56%+105.14% 40.3B
-2.13%-1.64%+7.51%+50.31% 30.59B
-0.46%-1.28%+31.47%+19.93% 28.16B
+5.32%+0.06%-7.20%-11.30% 24.36B
Average +0.85%-2.66%+45.97%+112.35% 41.84B
Weighted average by Cap. +0.61%-2.94%+47.30%+116.51%

Financials

2026 *2027 *
Net sales 17.42B 15.55B 14.47B 13.16B 24.85B 1,685B 24.96B 174B 68.23B 859B 65.4B 63.97B 2,758B 18.47B 16.49B 15.34B 13.96B 26.35B 1,787B 26.47B 185B 72.36B 911B 69.35B 67.84B 2,924B
Net income 1.27B 1.14B 1.06B 963M 1.82B 123B 1.83B 12.75B 5B 62.91B 4.79B 4.68B 202B 1.57B 1.41B 1.31B 1.19B 2.25B 152B 2.26B 15.74B 6.17B 77.66B 5.91B 5.78B 249B
Net Debt 13.84B 12.36B 11.5B 10.46B 19.75B 1,340B 19.83B 138B 54.23B 683B 51.98B 50.84B 2,192B 13.15B 11.75B 10.93B 9.94B 18.76B 1,273B 18.85B 132B 51.52B 649B 49.39B 48.31B 2,082B
Logo Iqvia Holdings
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (40.6%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (4.9%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (47.5%), Europe and Africa (31.8%) and Asia/Pacific (20.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Iqvia Holdings